⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587511 | 0.93 | — | — | |
| SCHEMBL6588538 | 0.90 | — | — | |
| SCHEMBL4441642 | 0.90 | — | — | |
| SCHEMBL6585726 | 0.90 | — | — | |
| SCHEMBL1220217 | 0.86 | — | — | |
| SCHEMBL7480929 | 0.67 | — | — | |
| SCHEMBL3124466 | 0.67 | — | — | |
| SCHEMBL8387588 | 0.65 | LMNA (0.30) | — | |
| SCHEMBL272617 | 0.65 | — | — | |
| SCHEMBL960157 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973832-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-13 | — | — | US | claimed |
| US-20200253982-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2020-08-13 | — | — | US | claimed |
| CN-106831541-B | Muscarinic M 1 receptor agonists | 赫普泰雅治疗有限公司 | 2019-09-06 | — | — | CN | claimed |
| CN-105980387-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2019-04-19 | — | — | CN | claimed |
| US-10259802-B2 | Bicyclic aza compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-04-16 | — | — | US | claimed |
| US-20180258085-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-09-13 | — | — | US | claimed |
| US-9975890-B2 | Bicyclic AZA compounds as muscarinic M1 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-05-22 | — | — | US | claimed |
| US-9907805-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-20170247369-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-31 | — | — | US | claimed |
| US-20160068508-A1 | Muscarinic M1 Receptor Agonists | NXERA PHARMA UK LIMITED (GB) | 2016-03-10 | — | — | US | claimed |
| US-9266857-B2 | Bicyclic AZA compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-23 | — | — | US | claimed |
| US-9187451-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-11-17 | — | — | US | claimed |
| US-20150232443-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-08-20 | — | — | US | claimed |
| EP-2897948-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2015-07-29 | — | — | EP | claimed |
| CN-104640851-A | Bicyclic aza compounds as muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LTD | 2015-05-20 | — | — | CN | claimed |
| US-20140329803-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2014-11-06 | — | — | US | claimed |
| EP-2780015-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | Heptares Therapeutics Limited (GB) | 2014-09-24 | — | — | EP | claimed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | claimed |
| WO-2013072705-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-05-23 | — | — | WO | claimed |